Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen in Subjects With Early Alzheimer's Disease (AD)

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen in Subjects With Early Alzheimer's Disease (AD)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buntanetap (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Acronyms DISCOVER
  • Sponsors Annovis Bio

Most Recent Events

  • 22 Oct 2024 According to Annovis Bio media release, data from the study will be presented as poster presentation at the 17th Clinical Trials on Alzheimers Disease (CTAD) conference. The event will be held from October 29 to November 1, 2024, in Madrid, Spain.
  • 01 Apr 2024 Results that supports understanding of Buntanetaps mechanism of action in humans presented in the Annovis Bio Media Release.
  • 18 Jul 2023 According to an Annovis Bio media release, data from this trial was presented in a posters presentation by Don Elbert, Ph.D., at the Alzheimer's Association International Conference (AAIC) 2023 annual meeting held in Amsterdam, Netherlands, from July 16 - 20.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top